Bristol-Myers Squibb Company (BMY)

70.36
+0.21(+0.30%)
After Hours
70.36
0.00(0.00%)
- Real-time Data
  • Volume:
    12,003,056
  • Day's Range:
    70.19 - 71.50
  • 52 wk Range:
    53.22 - 80.59

BMY Overview

Prev. Close
70.15
Day's Range
70.19-71.5
Revenue
46.96B
Open
70.74
52 wk Range
53.22-80.59
EPS
3.04
Volume
12,003,056
Market Cap
150.24B
Dividend (Yield)
2.16
(3.07%)
Average Vol. (3m)
9,647,028
P/E Ratio
23.23
Beta
0.423
1-Year Change
17.58%
Shares Outstanding
2,135,255,158
Next Earnings Date
Oct 26, 2022
What is your sentiment on Bristol-Myers Squibb?
or
Market is currently closed. Voting is open during market hours.

Bristol-Myers Squibb Company News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Bristol-Myers Squibb Company Analysis

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company Company Profile

Employees
30250

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Read More

Analyst Price Target

Average80.32 (+14.16% Upside)
High94
Low61
Price70.36
No. of Analysts23
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellSellSellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • time for reversal. Price is at support. short are going to lock some profits
    0
    • time for reversal. Price is at support. short are going to lock some profits
      0
      • TIME TO SELL
        4
        • Still undervalued at 76. I got in at 56, plan to ride it long term.
          0
      • Moin soon!
        0
        • on Market Mairacle advisors have published a purchase signal
          1
          • to the moon
            1
            • Moving on, investors are simply no longer interested in this stock and the executives are not doing anything about it
              1
              • There’s just no interest, as the price is already very cheap compared to its value. Perhaps that’s what BMY wants in order to buy back its stock cheap
                0
              • They barely have a few billion each year to buy back stock. Its a bad strategy.
                0
              • Ciprian Gal they have generated 12 billion dollar cash from operation in the last 9 months. They used 3,2 Billion to pay dividened, 6 billion to pay dept and 3,5 billion to buy back shares and they still have, 15 Billion in cash and short term investment in the balance sheet.   I think you were checking the wrong reports :D how much more money a company need? :D
                0
            • welcome to $52 ?
              2
              • Analysis dont care for bmy or phizer and they are the most respectfull and profitable in their area
                0
                • sold half of stock at loss. 57.5 is resistance from here on. Investors are not excited about this as a long term play (due to concerns growth). I'll return here to buy at a later time, when it makes sense to do so. Apparently with this pharma stock it was too soon to invest (as a value play). I'm eating my pride and moving on. Good luck to all.
                  3
                  • Market is also upset that they do not use cash to make investments.
                    0